4//SEC Filing
Mattes Glenn R. 4
Accession 0001213900-20-023893
CIK 0001733413other
Filed
Aug 25, 8:00 PM ET
Accepted
Aug 26, 6:14 PM ET
Size
8.4 KB
Accession
0001213900-20-023893
Insider Transaction Report
Form 4
Mattes Glenn R.
DirectorPresident and CEO
Transactions
- Award
Stock Options (Right to Buy)
2020-08-24+152,000→ 1,213,057 totalExercise: $13.65→ Common Stock (152,000 underlying) - Award
Stock Options (Right to Buy)
2019-11-29+89,952→ 1,061,057 totalExercise: $5.00→ Common Stock (89,952 underlying)
Footnotes (2)
- [F1]Represents top-up options required to be granted to reporting person upon conclusion of the Company's' s October 2019 IPO, as disclosed in the Company's IPO prospectus dated October 24, 2019. The Company had previously awarded the reporting person certain top-up options following the conclusion of the IPO, however, due to an arithmetic error, the Company awarded the reporting person 89,952 less top-up options than required under the reporting person's contract with the Company. Each Option shall vest and first become exercisable as follows: one-quarter of the options shall vest and first become exercisable on November 29, 2020 and the remainder of the options shall vest and first become exercisable in 12 equal quarterly installments commencing on February 29, 2021.
- [F2]Each Option shall vest and first become exercisable as follows: one-quarter of the Option shall vest and first become exercisable on August 24, 2021 and the remainder of the Option shall vest and first become exercisable in 12 equal quarterly installments commencing on November 24, 2021.
Documents
Issuer
TFF Pharmaceuticals, Inc.
CIK 0001733413
Entity typeother
Related Parties
1- filerCIK 0001568678
Filing Metadata
- Form type
- 4
- Filed
- Aug 25, 8:00 PM ET
- Accepted
- Aug 26, 6:14 PM ET
- Size
- 8.4 KB